UCB Frustrated By FDA Failure To Inspect Facility For Psoriasis Drug
Delays Expected Approval Of Bimekizumab
Executive Summary
The Belgian group is the latest to be hit by the FDA's difficulties in address the growing backlog of facility inspections, leaving bimekizumab in limbo in the US, despite having just been approved as Bimzelx in Europe.
You may also be interested in...
UCB Rocked By US FDA Rejection Of Blockbuster-In-Waiting Bimzelx
The Belgian group’s US launch of Bimzelx could be delayed by up to a year after the FDA hit UCB with a complete response letter which states that "certain pre-approval inspection observations must be resolved” before the drug can get the green light for psoriasis.
Big Year For UCB As Bimzelx Awaits US Green Light
The Brussels-based company's head of immunology has told Scrip that going into a crowded market against several highly effective biologics across different classes holds no fears for UCB despite some concerns that US prescribers will stick to what they know when it comes to psoriasis therapies.
UCB’s Bimzelx Impresses In Psoriatic Arthritis Amid US Psoriasis Approval Delay
UCB’s Bimzelx has forged ahead with success in a late-stage psoriatic arthritis trial while it still awaits US approval for psoriasis, a hotly anticipated blockbuster indication.